期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨髓增生异常综合征的表观遗传调控及其药物治疗新进展 被引量：1

原文传递
导出
摘要 骨髓增生异常综合征（MDS）是一组异质性明显的造血干细胞恶性克隆性疾病，以无效造血，骨髓造血干／祖细胞凋亡增加，程度不等的一系或多系血细胞减少以及向急性髓细胞白血病转化的高风险为特点。2008年世界卫生组织（who）明确将MDS与急性髓系白血病（AML）、骨髓增殖性肿瘤（MPN）等并列为五大髓系恶性肿瘤。
作者 郭青 张翼鷟
机构地区 天津医科大学附属肿瘤医院血液科天津市肿瘤防治重点实验室
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第16期1145-1147,共3页 National Medical Journal of China
关键词 骨髓增生异常综合征 表观遗传调控 药物治疗 急性髓系白血病 恶性克隆性疾病 造血干细胞 世界卫生组织 恶性肿瘤
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献25

  • 1Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med, 2011, 364:2496-2506.
  • 2Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009.41:838-842.
  • 3Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Me(t, 2009, 360:2289-2301.
  • 4Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114:3285-3291.
  • 5Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next- generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 2010, 116: 3923-3932.
  • 6Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet, 2009, 10 : 805-$11.
  • 7Jeong S, Liang G, Sharma S, et al. Selective anchoring of DNA methyhransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol, 2009, 29: 5366-5376.
  • 8Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 2011,25 :1153-1158.
  • 9Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZI-I2 in myeloid disorders. Nat Genet, 2010, 42:722-726.
  • 10Makishima H, Jankowska AM, Tiu RV, et al. Novel homo- and hemizygous mutations in EZI-12 in myeloid malignancies. Leukemia, 2010, 24:1799-1804.

同被引文献14

  • 1Hoffman B, Amanullah M, Shafarenko M, et al. The proto- oncogene c-rnyc in hematopoietic development and leukemogenesis. Oncogene, 2002, 21: 3414-3421.
  • 2Luo H, Li Q, O'Neal J, et al. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma- associated antiapoptotic mutations. Blood, 2005, 106: 2452- 2461.
  • 3Tondreau T, MeuIeman N, Delforge A, eta]. Mesencbymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells, 2005,23 : 1105-1112.
  • 4Lwiu T, Lin J, Chni YS, et al. Follicular dendritic cell- dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-roediated Bim down-regulation through induction of microRNA-18la. Blood, 2010, 116: 5228-5236.
  • 5Lin J, Lwin T, Zhao JJ, et al. Follicular dendritic cell-induced microRNA- mediated upregulation of PRDMI and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia,2011 , 25 : 145-152.
  • 6Carrancio S, Blanco B, Romo C, et al. Bone mmTow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone mmTow microenvironment. PLoS One, 2011, 6:e26241.
  • 7Schraufstatter IU, Discipio RG, Khaldoyanidi S. Mesenchymal stem cells and their microenvironment. Front Bosci, 2011, 16: 2271-2288.
  • 8Vianello F, Villanova F, Tisato V, et al. Bone marrow mesenehymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-indueed apoptosis via the CXCR4/ CXCL12 axis. Haematologica, 2010,95 : 1081-1089.
  • 9v Dang CV. MYC on the path to cancer. Cell, 2012,149:22-35.
  • 10Zhang Y, Zhao X, Tao J. Epigenetics, c-Myc and aggressive B- cell lymphornas. Oneotarget, 2012, 3 : 1264-1265.

引证文献1

二级引证文献3

中华医学杂志
2012年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部